Biogen Inc.BIIBNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-30.25%
↓ 607% below average
Average (39q)
5.96%
Historical baseline
Range
High:116.39%
Low:-69.00%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -30.25% |
| Q2 2025 | -2.93% |
| Q1 2025 | -20.13% |
| Q4 2024 | 1.56% |
| Q3 2024 | 13.62% |
| Q2 2024 | 13.10% |
| Q1 2024 | -19.12% |
| Q4 2023 | -18.78% |
| Q3 2023 | 25.13% |
| Q2 2023 | 2.63% |
| Q1 2023 | -20.06% |
| Q4 2022 | 28.22% |
| Q3 2022 | 1.61% |
| Q2 2022 | -3.64% |
| Q1 2022 | -19.41% |
| Q4 2021 | -5.63% |
| Q3 2021 | -32.62% |
| Q2 2021 | 97.16% |
| Q1 2021 | -69.00% |
| Q4 2020 | 61.45% |
| Q3 2020 | 72.54% |
| Q2 2020 | 13.86% |
| Q1 2020 | -9.96% |
| Q4 2019 | 28.00% |
| Q3 2019 | 11.47% |
| Q2 2019 | -14.00% |
| Q1 2019 | -7.83% |
| Q4 2018 | 14.23% |
| Q3 2018 | -49.30% |
| Q2 2018 | 108.41% |
| Q1 2018 | -13.77% |
| Q4 2017 | 31.63% |
| Q3 2017 | -51.28% |
| Q2 2017 | 116.39% |
| Q1 2017 | -20.70% |
| Q4 2016 | 0.93% |
| Q3 2016 | 11.82% |
| Q2 2016 | 8.19% |
| Q1 2016 | -19.27% |
| Q4 2015 | 4.19% |